Skip to content
Dx

ICD-10-CM 2027 diagnosis code

Q85.83Von Hippel-Lindau syndrome

✓ Billable / specificPOA exemptCC — complication/comorbidity

Q85.83 is a valid, billable ICD-10-CM code for von hippel-lindau syndrome. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Looking up by condition? See ICD-10 code for Lindau disease, ICD-10 code for Hippel's disease, ICD-10 code for Von Hippel disease or syndrome.

Code last changed in FY2023 (effective October 1, 2022). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About Q85.83

Q85.83 is the ICD-10-CM diagnosis code for von Hippel-Lindau syndrome. It belongs to category Q85 (phakomatoses, not elsewhere classified), block Q80-Q89 (other congenital malformations) and chapter 17 (congenital malformations, deformations, chromosomal abnormalities, and genetic disorders). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within Q85.8 (other phakomatoses, not elsewhere classified), Q85.83 is specifically for von Hippel-Lindau syndrome. Related codes cover PTEN hamartoma tumor syndrome (Q85.81), other Cowden syndrome (Q85.82) and other phakomatoses, not elsewhere classified (Q85.89).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC, relative weight 4.7581), DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC, relative weight 2.3896), DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC, relative weight 1.6955), DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC, relative weight 3.1281), DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC, relative weight 1.4859), DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC, relative weight 1.9453) and 2 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.

It was added in FY2023, effective October 1, 2022.

Coding notes

Code alsoTwo codes may be needed; sequencing depends on circumstances
  • manifestations

Notes that apply from higher levels

Instructions written at a parent level also apply to Q85.83.

› From Q85.8 Other phakomatoses, not elsewhere classified
Excludes1
  • Meckel-Gruber syndrome (Q61.9)
› From Q85 Phakomatoses, not elsewhere classified
Excludes1
  • ataxia telangiectasia [Louis-Bar] (G11.3)
  • familial dysautonomia [Riley-Day] (G90.1)

Broader instructions also apply from Chapter 17: Congenital malformations, deformations, chromosomal abnormalities, and genetic disorders.

Alphabetic index entries

4 entries

Terms in the official ICD-10-CM index that lead to Q85.83.

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2023 (effective 10/1/2022): Added
  • No changes since FY2023.

Common questions about Q85.83

Is Q85.83 billable?

Yes. Q85.83 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can Q85.83 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict Q85.83 as a principal diagnosis.

Is Q85.83 a CC or MCC?

Q85.83 is a CC (complication or comorbidity) under MS-DRG v44.0, unless excluded by the principal diagnosis.

What DRG does Q85.83 group to?

Q85.83 is used in the MS-DRG v44.0 logic for MS-DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC), MS-DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC), MS-DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC), MS-DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC), MS-DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC), MS-DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC) and 2 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.